Review Article
The Role of MicroRNAs in Regulating Cytokines and Growth Factors in Coronary Artery Disease: The Ins and Outs

Armita Mahdavi Gorabi,1 Nasim Kiaie,1 Thozhukat Sathyapalan,2 Khalid Al-Rasadi,3 Tannaz Jamialahmadi,4,5,6 and Amirhossein Sahebkar7,8,9,10

1Research Center for Advanced Technologies in Cardiovascular Medicine, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
2Department of Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull, UK
3Medical Research Centre, Sultan Qaboos University, Muscat, Oman
4Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
5Department of Food Science and Technology, Quchan Branch, Islamic Azad University, Quchan, Iran
6Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
7Halal Research Center of IRI, FDA, Tehran, Iran
8Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran
9Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
10School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Correspondence should be addressed to Amirhossein Sahebkar; amir_saheb2000@yahoo.com

Received 28 March 2020; Revised 7 July 2020; Accepted 11 July 2020; Published 25 July 2020

Copyright © 2020 Armita Mahdavi Gorabi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Coronary artery diseases (CAD), as a leading cause of mortality around the world, has attracted the researchers’ attention for years to find out its underlying mechanisms and causes. Among the various key players in the pathogenesis of CAD cytokines, microRNAs (miRNAs) are crucial. In this study, besides providing a comprehensive overview of the involvement of cytokines, growth factors, and miRNAs in CAD, the interplay between miRNA with cytokine or growth factors during the development of CAD is discussed.

1. Introduction

Coronary artery disease (CAD) involves all diseases in which blood flow to the heart muscles is restricted. Plaque formation resulting from coronary atherosclerosis is the main reason for blood flow restriction. Destabilization and subsequent rupture of plaque might produce acute coronary syndrome (ACS), which is classified into unstable angina (UA), ST-segment elevation myocardial infarction (STEMI), and acute myocardial infarction (AMI) which differ in the extent of involvement of cardiac muscles and release of cardiac markers [1].

Cytokines, a broad category of small polypeptides of less than 80 kDa including chemokines and growth factors that are released from cells locally and potentially contribute to the initiation of coronary artery disease [2]. Inflammatory cytokines and growth factors are involved in various pathways involved in the development of CAD including STAT, MAPK, and SMAD [3, 4].

miRNAs are a class of small (20-25 nucleotides) noncoding RNAs which affects various molecular pathways, altering gene expression and regulating cytokine production [5]. The mechanism by which miRNA regulates gene expression includes miRNA binding to the 3′ untranslated region...
(UTR) of the target gene, destabilizing the mRNA, translation repression thereby inhibiting protein synthesis [6]. To protect miRNA from degradation by plasma enzymes, they are packed in exosomes, proteins, and most abundantly in CD31+ microparticles, which are released from the endothelial cells (ECs) and platelets [7–9]. Besides this packaging mechanism, miRNAs which are highly stable in plasma makes it a suitable choice for use as diagnostic biomarkers for various disorders [10].

Both cytokines and miRNAs are components of the signaling pathways that carry out essential cellular functions, and in some cases, drive disease progression. In this review, the distinct contribution of cytokines, growth factors, and miRNAs in CAD is presented, and then the relationship between miRNA and cytokine or growth factors in CAD progression is reviewed.

2. CAD-Related Cytokines and Growth Factor

It is well established that inflammation is an integral part of CAD. Therefore, inflammatory cytokines in the peripheral blood produced after caspase-1 pathway activation from macrophages and lymphocytes, are important players in the progression of CAD [11]. Serum levels of T helper cytokines, including proinflammatory Th1 type and anti-inflammatory Th2 type cytokines, are good CAD risk indicators. In general, stimulation of Th1 and Th2 suppression contributes to the development of CAD following type 2 diabetes mellitus [12]. Th1 type, especially interferon-gamma (IFN-γ), has a prominent role in the initiation of CAD and transforming stable angina to unstable angina via macrophage activation, weakening of the atherosclerotic plaque’s fibrous cap and plaque rupture [13, 14]. In contrast, Th2 cytokines such as interleukin IL-4 and IL-10 deactivate macrophages and stabilize the plaque [15].

Circulating levels of IL-1β and its receptor are a significant marker of atherogenesis and CAD [11, 16]. IL-18 is another cytokine that is related to the severity of CAD [17]. In one clinical study, patients with ACS had not only higher IL-1β and IL-18 but also IL-6, a downstream cytokine to the two cytokines above than in patients with stable CAD [18]. However, the role of IL-6 in CAD is complex since elevated plasma levels of IL-6 are associated with cardiovascular risk and formation of atherosclerotic plaque, it could exert an inhibitory effect on other inflammatory cytokines such as IL-1 [19]. An in vitro study on the peripheral blood mononuclear cells of patients with CAD showed that expression of cytokines including CCL2, CXCL8, CXCL9, CXCL10, IFN-γ, and IL-10 increase in both stable or unstable angina (UA) groups. The only difference between these two groups was lower IL-10 mRNA expression in the UA group [20]. The ratio of IL-18/IL-10, as well as levels of C-reactive protein (CRP), a cytokine mediator, is considered diagnostic tools for premature CAD with high sensitivity and specificity. An elevated CRP represents more severe CAD [21].

Bolez et al. demonstrated that increased plasma level of INF-γ, tumor necrosis factor-alpha (TNF-α), IL-1β, and IL-8 cytokines, as well as reduced secretion of IL-2 from activated T-cells and IL-4 from T helper cells (Th2 type), is a characteristic of coronary artery ectasia, a kind of CAD distinguished by at least 1.5-fold expansion of the artery [22]. TNF-α with genetically altered promoter region affects the development of CAD in patients suffering from nonalcoholic fatty liver disease. Patients carrying TNF-α-238 guanine to alanine (GA) polymorphism are more prone to the development of CAD [23].

A study of 180 patients with stable angina showed NOGO-B/NUS1 and TL1A/DR3 cytokines were increased in CAD. The ADAMTS-5 cytokine, which is expressed in the macrophages during the differentiation of monocytes to macrophages, were increased in CAD while it was reduced in patients with peripheral artery disease (PAD). TNF-like cytokine 1A (TL1A) axis, after interaction with its receptor, death receptor 3 (DR3), initiates proinflammatory pathways in atherosclerosis [24].

Clinical studies also showed there is a direct correlation between increased levels of proinflammatory cytokines (IFN-γ, TNFa, IL-2, IL-6, IL-9, and IL-17) and anti-inflammatory cytokines (IL-4 and IL10) with the severity of CAD determined by coronary angiography [25, 26]. In a retrospective case-control study, IL-5 level was associated with coronary heart disease. The cytokine, which was most strongly associated with the risk of coronary heart disease, was IL-6 [27]. Increased number of Th9 cells and its related cytokine, IL-9, were also associated with atherosclerosis through mediating infiltration of inflammatory cells into the atherosclerotic plaques [28]. Suppression of transforming growth factor-beta (TGF-β) cytokine is another characteristic feature of CAD [29]. A meta-analysis of prospective studies showed that there was no significant correlation between heart disease and the levels of soluble forms of CD40 ligand (sCD40L) and matrix metalloproteinase (MMP)-9 cytokines [30].

3. CAD-Related miRNAs

Numerous studies have shown that miRNAs are involved in CAD and related conditions owing to the role of miRNAs in regulating the function of cells, including endothelial cells (EC), smooth muscle cells (SMC), and macrophages, as well as in inflammation and other metabolic processes. The expression of miRNAs is specific to the cell type. For example, miRNA-222 is expressed in endothelial cells and vascular SMCs, 126-3p, and miR-21 are detected in ECs of vascular tissues, platelets, and bone marrow-derived cells and miR-499 and miR-133a are expressed in muscle cells [31–33]. In CAD and related diseases, expression of these miRNAs is up or downregulated. An example is the upregulation of fibrosis-related miRNAs (miR-29b) and inflammation-related miRNAs (miR-124a, miR-146a, miR-155, and miR-223) in abdominal aortic aneurysm (AAA) [34]. After upregulation, some miRNAs are released into the circulation. For example, miR-499 and miR-133a are released into the blood following myocardial injury [32, 33]. The circulating levels of miRNAs, as illustrated in Table 1, increase or decrease in response to various coronary diseases. These changes in the level of miRNAs in extracellular fluids and circulation open new doors for the early detection of CAD. A number of these
| miRNA | Increase in level | Cytokine & growth factor | Decrease in level | Cytokine & growth factor |
|-------|------------------|--------------------------|------------------|--------------------------|
| miR-1 | miR-17-5p        | INF-γ                    | miR-10a          | miR-29a/b                 |
| miR-21| miR-133a-3p      | TNF-α                    | miR-17           | miR-30e-5p                |
| miR-23a| miR-146a/b       | IL-1β                    | miR-19a          | miR-92a/b                 |
| miR-24| miR-191-3p       | IL-18                    | miR-22           | miR-93-5p                 |
| miR-25| miR-361-5p       | Nogob/Nus1               | miR-23a          | miR-126-5p                |
| miR-33a| miR-560-5p       | IL-8                     | miR-31           | miR-140-3p                |
| miR-34a| miR-574-5p       | TL1a/R                   | miR-126          | miR-181d                  |
| miR-92a| miR-615-5p       | AdamsS                   | miR-133          | miR-199a                  |
| miR-122| miR-313-5b       | CRP                      | miR-145          | miR-195                   |
| miR-133a| miR-370         | IL-6, IL-9               | miR-8059         | miR-6816-3p               |
| miR-126| miR-106b         | IL-17-5p                 | miR-138-2-3p     | IL-2                     |
| miR-134| miR-103a         | IL-17-5p                 | miR-138-2-3p     | IL-4                     |
| miR-135a| miR-483         | INF-γ                    | miR-147          | IL-10                    |
| miR-191| miR-208a         | IL-17-5p                 | miR-150          | IL-10                    |
| miR-197| miR-502          | IL-17-5p                 | miR-150          | IL-10                    |
| CAD   |                  |                           |                 |                           |
| miR-21| miR-99a          | IL-1β                    | miR-100          | miR-1181                  |
| miR-92a| miR-370         | IL-6, IL-9               | miR-8059         | miR-6816-3p               |
| miR-486-5p| miR-19a-5p   | IL-1β                    | miR-19a/b        | IL-2                     |
| CA    |                  |                           |                 |                           |
| miR-320a| miR-92a         | IL-1β                    | miR-106          | IL-6                     |
| miR-133a| miR-186         | IL-1β                    | miR-106          | IL-6                     |
| miR-208b| miR-210         | IL-1β                    | miR-106          | IL-6                     |
| miR-135a| miR-483         | INF-γ                    | miR-147          | IL-10                    |
| miR-140-3p| miR-499       | IL-17-5p                 | miR-150          | IL-10                    |
| miR-142-5p| miR-134a-5p  | MCP-1                    | miR-150          | IL-10                    |
| UA    |                  |                           |                 |                           |
| miR-208| miR-133a        | IL-1β                    | miR-106          | IL-6                     |
| miR-34a| miR-320a        | IL-1β                    | miR-106          | IL-6                     |
| miR-423| miR-486a        | IL-1β                    | miR-106          | IL-6                     |
| AMI   |                  |                           |                 |                           |
| miR-136| miR-126-5p      | IL-1β                    | miR-106          | IL-6                     |
| miR-29b| miR-145-3p      | IL-1β                    | miR-106          | IL-6                     |
| miR-194| miR-17-5p       | IL-1β                    | miR-106          | IL-6                     |
| miR-499| miR-328-5p      | IL-1β                    | miR-106          | IL-6                     |
| STEMI |                  |                           |                 |                           |
| miR-1  | IL-2            | miR-15a-5p               | miR-320a         | IL-6                     |
| miR-30d| IL-6            | miR-19a-5p               | miR-320a         | IL-6                     |
| miR-133| IL-8            | miR-30e-5p               | miR-25-5p        | IL-6                     |
| miR-208| IL-10           | miR-30a-5p               | miR-16-5p        | IL-6                     |
| miR-423| miR-101-3p      | miR-101-5p               | miR-10a          | IL-6                     |
| miR-499| miR-328-5p      | miR-107                  | miR-107          | IL-6                     |
|       |                 | miR-744-5p               | miR-375          | IL-6                     |
|       |                 | miR-103a-3p              | miR-375          | IL-6                     |
|       |                 | miR-1307-5p              | miR-375          | IL-6                     |
|       |                 | miR-409-5p               | miR-375          | IL-6                     |
|       |                 | miR-181b-5p              | miR-375          | IL-6                     |
|       |                 | miR-181a-5p              | miR-375          | IL-6                     |

CAD: coronary artery disease; CA: coronary atherosclerosis; UA: unstable angina; AMI: acute myocardial infarction; STEMI: ST-segment elevated myocardial infarction; Ra: receptor antagonist; MCSF: macrophage colony-stimulating factor; MCP-1: monocyte chemoattractant protein-1; INF-γ: interferon-gamma, TNF-α: tumor necrosis factor-alpha; IL: interleukin; CRP: C-reactive protein.
miRNAs and their alteration in response to disease are evaluated clinically for diagnostic purposes.

Among these miRNAs, some have more sensitivity and specificity to the disease model. For example, increased levels of miR-21, miR-92, miR-126, and miR-132 are highly specific to the UA [35–40], while a combination of miR-126, miR-197, and miR-223 is specific for AMI [41]. There are confounding factors in the measurement of miRNA levels that should not be forgotten. Studies have shown that many factors, including administration of heparin, aspirin, antiplatelet agents, statins, and angiotensin-converting enzyme (ACE) inhibitors before blood sampling from patients, as well as endogenous heparin can affect miRNA quantification [42–47].

Measuring the circulating levels of some miRNAs enables the assessment of disease severity. For example, expression of miR-574-5p in CAD increases proportionally to the severity of the disease [48]. Furthermore, coronary artery calcification leads to reduced expression of miR-138-2-3p, miR-1181, miR-6816-3p, and miR-8059, among them the correlation between miRNA-8059 expression and the level of coronary calcification predicts the severity of the disease [49].

Some miRNAs, such as miR-126-3p, miR-132, miR-140-3p, miR-197, miR-210, and miR-223 are not only involved in the various coronary diseases but also could predict the mortality in angiographically documented CAD patients [50].

Some miRNAs are correlated to the composition of atherosclerotic plaques. For example, miR-100 is released from vulnerable coronary plaques, and its plasma levels are associated with plaque composition as determined by integrated backscatter intravascular ultrasound (IB-IVUS). miR-100 is strongly correlated with the percentage of lipid volume and negatively correlated with fibrous volume [51].

4. Regulating CAD-Related miRNAs by Cytokines and Growth Factors

While many studies dealt with the role of miRNAs or cytokines in CAD, it should be noticed that the contribution of both miRNA and cytokine in CAD is more complicated since these two factors affect each other’s expression (see Figure 1). Researchers have been trying to elucidate the mechanism by which miRNAs affects CAD and related disease processes by studying the most probable target genes for CAD-related miRNAs using targetscore algorithm [52]. Paying attention to the relationship between miRNA, cytokines, and growth factors not only shed light on these mechanisms but also leads to a better understanding of whether miRNA or cytokine and growth factors are more suitable targets for CAD therapeutics.

4.1. Growth Factors. Growth factors are important cytokines that could alter miRNA expression. Treatment of ECs with vascular endothelial growth factor (VEGF) results in the induction of miR-17–92 cluster and alteration of miRNA expression [53]. Treatment of human umbilical vein endothelial cells (HUVECs) with VEGF and beta fibroblast growth factor (bFGF) upregulated miR-132 3–6 h after treatment via induction of cAMP-response element-binding protein (CREB), an essential element for miR-132 transcription [54]. Suarez et al. showed that treatment of HUVECs with proinflammatory cytokine, TNF, increased the expression of miR-17-5p, miR-31, miR-155, and miR-191 [55]. Exposure of ECs to IL-3 or bFGF, activators of the STAT5 signaling pathway, decreased the expression of miR-222 [56].

4.2. Inflammatory Cytokines. A correlation exists between miRNAs and proinflammatory cytokines so that signal intensity of monocyte chemoattractant protein (MCP-1) cytokine decreased with increasing expression of miR-22, miR-124, miR-146a, and miR-223 [34, 57]. Likewise, such relation exists between TNF-α and miR-126 and miR-19b, or TGF-β and miR-146a [34, 58]. Additionally, IL-1β induce miR-146a/b expression in ECs [59]. THP-1 cells, a monocytic cell line, when treated with IL-1β, activated TLR/IL-1R signaling which leads to NF-κB activation and increased miR-146a expression up to 15-fold during 24 h [60]. Stimulating miR-29 mimics-transfected immortalized human bronchial epithelial cells (BEAS-2B) as a model of allergic inflammation with TNF-α and IL-4 cytokines for 48 hours lead to both upregulation of endogenous miR-29 expression and increasing soluble ST2, an inflammation-related gene and a receptor for IL-33. However, miR-29 overexpression decreased soluble ST2 mRNA expression [61].

5. Regulating CAD-Related Cytokines and Growth Factors by miRNAs

miRNAs regulate cytokine and growth factors production and release by two distinct mechanisms: they directly bind to 3′UTR target site in cytokine, or they affect binding proteins containing adenine and uridine elements (ARE-BPs) and consequently affect cytokine or growth factors stability and production. Some ARE-BPs include tristetraprolin (TTP), AU-rich binding factor 1 (AUF1) and members of the Hu protein R (HUR) family, which exist in some, but not all cytokines [62].

5.1. VEGF. miRNAs might directly target growth factors. CAD-related miRNAs including miR-16, miR-20a, miR-20b, let-7b, miR-17-5p, miR-27a, miR-106a, miR-106b, miR-107, miR-193a, miR-210, miR-320, and miR-361, have been recognized to target VEGF and bind VEGF 3′UTR through nt160–195 binding site [63]. Among CAD-related miRNAs, miR-15a, miR-16, miR-93, miR-200b, miR-361-5p, and miR-424 repress VEGF expression by affecting VEGF receptors, while miR-23, miR-126, miR-132, and miR-221 negatively regulate VEGF signaling pathway by targeting downstream of VEGF [64, 65]. In addition, miR-23a secreted from endothelial progenitor cells (EPCs) of CAD patients targets epidermal growth factor receptor (EGFR) and suppresses VEGF [66]. miRNA-31 and miRNA-720 block FAT4 and thromboxane A2 receptors of EPCs in CAD patients [67]. Since thromboxane A2 receptors have an inhibitory effect on VEGF signaling [68], miRNA-31 and miRNA-720 indirectly increase VEGF-induced angiogenesis. Fish et al. found that the response of ECs to VEGF is regulated by miR-126. The beneficial effect of miR-126 on
this cytokine is the inhibition of Sprouty-related protein SPRED1 and phosphoinositol-3 kinase regulatory subunit 2 (PIK3R2/p85-beta), two inhibitors of VEGF pathway, and therefore preserving VEGF signaling and maintaining vascular integrity [69]. In other disease models, such as tumor angiogenesis, the elevation of VEGF expression and secretion is observed following transfection of miR-181a in chondrosarcoma cell line JJ [70]. It is worth to notice that the levels of miR-181a reduction in ACS is not in favor of angiogenesis. miR-103 also decreased VEGF expression and vascular density in rats which underwent middle cerebral artery occlusion [71]. Transfecting SK-N-AS cell line with miR-93-5p altered expression of VEGF and IL-8, showing that the 3′ UTR region of these cytokines is a target for miR-93-5p [72].

5.2. TGF-β. TGF-β signaling, a critical factor for putting the stable atherosclerotic plaques at the risk of rupture, is affected by CAD-related miRNAs such as miR-21, miR-25, and miR-106b via the mechanism of affecting CDKN1A/p21 and BCL2L11/Bim [73–75]. miR-21 targets TGF-β and bone morphogenic protein (BMP) which results in the induction of contractility in vascular smooth muscle cells [76, 77]. Increasing miR-133a expression suppresses TGF-β1 and connective tissue growth factor (CTGF) expression. CTGF is an important cytokine produced from fibroblasts and downstream for TGF-β1 profibrotic pathway [78]. Therefore, miR-133a exerts a cardioprotective effect via suppressing this pathway and reducing fibrosis in MI [79].

5.3. Interleukins. Some CAD-related miRNAs, including miR-21, miR-126, miR-146a, miR-155, and miR-223 are considered to be inflammatory-related miRNAs [80]. Therefore, it is highly probable that these miRNAs affect the inflammatory cytokines to pull the inflammatory processes together. During atherosclerosis, apoptotic bodies are released from ECs which contain miRNAs such as miR-126. The release of these apoptotic bodies (or miR-126) stimulates CXCL12 production [81]. miR-146a/b affects toll-like receptor 4 (TLR4) signaling through regulating IL-1 receptor-associated kinase 1 (IRAK1) and TNF receptor-associated factor 6 (TRAF6), two downstream molecules to TLR4 [60, 82]. TLR4 stimulation by miRNAs is necessary since activation of this protein initiates signaling cascades, which lead to proinflammatory cytokine production which is the reason behind the regulatory role of miR-146a in inflammation during CAD progression [84]. Transfecting human vascular endothelial cell line (EA.hy926 cells) with
miR-146 mimic showed that this miRNA contributes to the inflammatory processes in sepsis disease via decreasing expression of inflammatory cytokines, including TNF-α, IL-6, and intercellular adhesion molecule (ICAM)-1, and E-selectin [85]. Transfecting natural killer cells with lentiviral vectors expressing miR-155 decreased the pro-inflammatory cytokines such as IL-1, IL-6, TNF-α, and IFN-γ [86]. A positive correlation also exists between IL-17 production by CD4+ T cells and miR-155 expression [87].

A study on human nasal epithelial cells (JME/CF15) treated with IL-13 as an in vitro model of allergic rhinitis showed there is association between miR-16 and inflammatory reactions so that miR-16 upregulation in JME/CF15 cells leads to inhibition of cytokines including granulocyte-macrophage colony-stimulating factor (GM-CSF), eotaxin, IL-1β, IL-6, and IL-10. The mechanism of the effect of miR-16 on inflammatory cytokines is governed by blocking IKKβ/NF-κB signaling pathways because miR-16 inhibit either IkB kinase β (IKKβ) expression or NF-κB activation [88]. Intranasal administration of an inhibitor of miR-21 (anti-miR-21 antagonist) to ovalbumin sensitized BALB/c mice, as a model of acute bronchial asthma, reduced the levels of IL-4 and airway inflammation [89]. A recent study found that transfecting CD4 T cells with miR-31 reduce the expression levels of IL-2 and IL-4 via targeting NF-κB and HIF-1α [90]. miR-150 is a negative regulator of IL-2 due to the interaction of cytokines such as growth factors and inflammatory cytokines on CAD-related miRNAs is elucidated, which could act as biomarkers or potential targets for therapeutics.

6. Conclusions

Although a large number of studies confirmed that alteration in the levels of specific cytokines, growth factors, and miRNAs represent CAD diseases, developing new therapeutics targeting cytokines and growth factors or miRNA has not been promising since cytokines and miRNA have a complicated network of interactions in CAD. In this review of CAD-related cytokines, growth factors, and miRNAs, the interaction of cytokines such as growth factors and inflammatory cytokines on CAD-related miRNAs is elucidated, which could act as biomarkers or potential targets for therapeutics.

Conflicts of Interest

The authors declare that they have no competing interests.

Authors’ Contributions

Armita Mahdavi Gorabi and Nasim Kiahie contributed equally to this paper.

References

[1] A. Kumar and C. P. Cannon, “Acute coronary syndromes: diagnosis and management, part I,” Mayo Clinic Proceedings, vol. 84, no. 10, pp. 917–938, 2009.

[2] J. J. O’Shea, M. Gadina, and R. Siegel, “9 - cytokines and cytokine receptors,” in Clinical Immunology, R. R. Rich, T. A. Fleisher, W. T. Shearer, H. W. Schroeder, A. J. Frew, and C. M. Weyand, Eds., pp. 108–135, Content Repository Only!, London, 4th edition, 2013.

[3] H. Mirzaii, A. G. Ferns, A. Avan, and M. G. Mobaran, “Chapter Two - cytokines and microRNA in coronary artery disease,” in Advances in Clinical Chemistry, G. S. Makowski, Ed., vol. 82, pp. 47–70, Elsevier, 2017.

[4] M. Fioranelli, A. G. Bottaccioli, F. Bottaccioli, M. Bianchi, M. Rovesti, and M. G. Roccia, “Stress and inflammation in coronary artery disease: a review psychoneuroendocrine-immunology-based,” Frontiers in Immunology, vol. 9, no. 2031, 2018.

[5] D. de Gonzalo-Calvo, E. Iglesias-Gutiérrez, and V. Llorente-Corriés, “Epigenetic biomarkers and cardiovascular disease: circulating microRNAs,” Revista Española de Cardiología (English Edition), vol. 70, no. 9, pp. 763–769, 2017.

[6] I. G. Cannell, W. Y. Kong, and M. Bushell, “How do microRNAs regulate gene expression?,” Biochemical Society Transactions, vol. 36, no. 6, pp. 1224–1231, 2008.

[7] J. Zhang, S. Li, L. Li et al., “Exosome and exosomal microRNA: trafficking, sorting, and function,” Genomics, Proteomics & Bioinformatics, vol. 13, no. 1, pp. 17–24, 2015.

[8] C. Camaioni, M. Gustapane, P. Gialdella, R. D. Bona, and L. M. Biasucci, “Microparticles and microRNAs: new players...
in the complex field of coagulation," *Internal and Emergency Medicine*, vol. 8, no. 4, pp. 291–296, 2013.

[9] P. Diehl, A. Fricke, L. Sanders et al., "Microparticles: major transport vehicles for distinct microRNAs in circulation," *Cardiovascular Research*, vol. 93, no. 4, pp. 633–644, 2012.

[10] C. Glinge, S. Claus, K. Boddum et al., "Stability of circulating blood-based microRNAs - pre-analytic methodological considerations," *PloS One*, vol. 12, no. 2, article e0167969, 2017.

[11] J. Galea, J. Armstrong, P. Gadsdon, H. Holden, S. E. Francis, and C. M. Holt, "Interleukin-1β in coronary arteries of patients with ischemic heart disease," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 16, no. 8, pp. 1000–1006, 1996.

[12] H. Madhumitha, V. Mohan, M. Deepa, S. Babu, and V. Aravindhan, "Increased Th1 and suppressed Th2 serum cytokine levels in subjects with diabetic coronary artery disease," *Cardiovascular Diabetology*, vol. 13, no. 1, p. 1, 2014.

[13] P. Szodoray, O. Timar, K. Veres et al., "TH1/TH2 imbalance, measured by circulating and intracytoplasmic inflammatory cytokines–immunological alterations in acute coronary syndrome and stable coronary artery disease," *Scandinavian Journal of Immunology*, vol. 64, no. 3, pp. 336–344, 2006.

[14] A. R. Fatkhullina, I. O. Peshkova, and E. K. Koltsova, "The role of cytokines in the development of atherosclerosis," *Biochemistry*, vol. 81, no. 11, pp. 1358–1370, 2016.

[15] D. A. Smith, S. D. Irving, J. Sheldon, D. Cole, and J. C. Kaski, "Serum levels of the anti-inflammatory cytokine interleukin-10 are decreased in patients with unstable angina," *Circulation*, vol. 104, no. 7, pp. 746–749, 2001.

[16] A. J. Lorenzatti and B. M. Retzlaff, "Unmet needs in the management of atherosclerotic cardiovascular disease: is there a role for emerging anti-inflammatory interventions?", *International Journal of Cardiology*, vol. 221, pp. 581–586, 2016.

[17] L. Wang, P. Qu, J. Zhao, and Y. Chang, "NLRP3 and downstream cytokine expression elevated in the monocytes of patients with coronary artery disease," *Archives of Medical Science*, vol. 4, no. 4, pp. 791–800, 2014.

[18] G. J. Martinez, S. Robertson, J. Barracough et al., "Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome," *Journal of the American Heart Association*, vol. 4, no. 8, article e002128, 2015.

[19] A. B. Reiss, N. M. Siegart, and J. De Leon, "Interleukin-6 in atherosclerosis: atherogenic or atheroprotective?", *Clinical Lipidology*, vol. 12, no. 1, pp. 14–23, 2017.

[20] R. T. D. de Oliveira, R. L. Mamoni, J. R. M. Souza et al., "Differential expression of cytokines, chemokines and chemokine receptors in patients with coronary artery disease," *International Journal of Cardiology*, vol. 136, no. 1, pp. 17–26, 2009.

[21] W. M. Ansari, "Sensitivity of cytokine and cytokine mediator detection aiding in diagnosis of premature coronary artery disease patients," *SOJ Immunology*, vol. 3, no. 1, 2015.

[22] U. Boles, A. Johansson, U. Wiklund et al., "Cytokine disturbances in coronary artery Ectasia do not support atherosclerosis pathogenesis," *International Journal of Molecular Sciences*, vol. 19, no. 1, p. 260, 2018.

[23] Y. Cheng, B. An, M. Jiang, Y. Xin, and S. Xuan, "Association of tumor necrosis factor-alpha polymorphisms and risk of coronary artery disease in patients with non-alcoholic fatty liver disease," *Hepatitis Monthly*, vol. 15, no. 3, article e26818, 2015.

[24] D. Ozkaramanli Gur, S. Guzel, A. Akyuz, S. Alpsoy, and N. Guler, "The role of novel cytokines in inflammation: defining peripheral artery disease among patients with coronary artery disease," *Vascular Medicine*, vol. 23, no. 5, pp. 428–436, 2018.

[25] X. Min, M. Lu, S. Tu et al., "Serum cytokine profile in relation to the severity of coronary artery disease," *BioMed Research International*, vol. 2017, Article ID 4013685, 9 pages, 2017.

[26] D. Radjabova, A. Al, A. Ba, T. Dk, Y. Li, N. Sk et al., "The Features of cytokine status in patients with coronary heart disease, Hypertension & Vascular Biology International Journal, MEDWIN PUBLISHERS, 2018.

[27] R. Clarke, E. Valdes-Marquez, M. Hill et al., "Plasma cytokines and risk of coronary heart disease in the PROCARDIS study," *Open Heart*, vol. 5, no. 1, article e000807, 2018.

[28] Q. Li, T. Ming, Y. Wang et al., "Increased Th9 cells and IL-9 levels accelerate disease progression in experimental atherosclerosis," *American Journal of Translational Research*, vol. 9, no. 3, pp. 1335–1343, 2017.

[29] Z. S. Sepehri, M. Masoomi, F. Ruzbeh et al., "Comparison of serum levels of IL-6, IL-8, TGF-β and TNF-α in coronary artery diseases, stable angina and participants with normal coronary artery," *Circulation and Molecular Biology*, vol. 64, no. 5, pp. 1–6, 2018.

[30] S. Kaptoge, S. R. K. Seshasai, P. Gao et al., "Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis," *European Heart Journal*, vol. 35, no. 9, pp. 578–589, 2014.

[31] F. Jansen, L. Schäfer, H. Wang et al., "Kinetics of circulating microRNAs in response to cardiac stress in patients with coronary artery disease," *Journal of the American Heart Association*, vol. 6, no. 8, 2017.

[32] M. F. Corsten, R. Dennert, S. Jochems et al., "Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease," *Circulation Cardiovascular Genetics*, vol. 3, no. 6, pp. 499–506, 2010.

[33] R. Wang, N. Li, Y. Zhang, Y. Ran, and J. Pu, "Circulating microRNAs are promising novel biomarkers of acute myocardial infarction," *Internal Medicine*, vol. 50, no. 17, pp. 1789–1795, 2011.

[34] K. Kin, S. Miyagawa, S. Fukushima et al., "Tissue- and plasma-specific MicroRNA signatures for atherosclerotic abdominal aortic aneurysm," *Journal of the American Heart Association*, vol. 1, no. 5, article e000745, 2012.

[35] Y. Kuwabara, K. Ono, T. Horie et al., "Increased MicroRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage," *Circulation: Cardiovascular Genetics*, vol. 4, no. 4, pp. 446–454, 2011.

[36] C. Widera, S. K. Gupta, J. M. Lorenzen et al., "Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome," *Journal of Molecular and Cellular Cardiology*, vol. 51, no. 5, pp. 872–875, 2011.

[37] T. Zeller, T. Keller, F. Ojeda et al., "Assessment of microRNAs in patients with unstable angina pectoris," *European Heart Journal*, vol. 35, no. 31, pp. 2106–2114, 2014.

[38] J. Ren, J. Zhang, N. Xu et al., "Signature of circulating microRNAs as potential biomarkers in vulnerable coronary artery disease," *PloS One*, vol. 8, no. 12, article e80738, 2013.

[39] Y. D'Alessandra, M. C. Carena, L. Spazzafumo et al., "Diagnostic potential of plasmatic microRNA signatures
in stable and unstable angina," PloS One, vol. 8, no. 11, article e80345, 2013.

[40] Y. Devaux, M. Mueller, P. Haaf et al., "Diagnostic and prognostic value of circulating microRNAs in patients with acute chest pain," Journal of Internal Medicine, vol. 277, no. 2, pp. 260–271, 2015.

[41] A. Zampetaki, P. Willett, L. Tilling et al., "Prospective study on circulating microRNAs and risk of myocardial infarction," Journal of the American College of Cardiology, vol. 60, no. 4, pp. 290–299, 2012.

[42] P. Willett, R. McGregor, H. S. Markus et al., "Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease," Thrombosis and Haemostasis, vol. 110, no. 9, pp. 609–615, 2017.

[43] J.-N. Boeckel, C. E. Thomé, D. Leistner, A. M. Zeiher, J.-N. Boeckel, C. E. Thomé, D. Leistner, A. M. Zeiher, M. Weber, M. B. Baker, R. S. Patel, A. A. Quyyumi, G. Bao, H.-W. Wang, T.-S. Huang, H.-H. Lo et al., "MicroRNA-222 controls neovascularization by regulating signal transducer and activator of transcription 5A expression," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 8, pp. 1562–1568, 2010.

[44] A. Boileau, C. L. L. Cardenas, M. E. Lindsay, and Y. Devaux, "Endogenous heparin interferes with quantification of microRNAs by RT-qPCR," Clinical Chemistry, vol. 64, no. 5, pp. 863–865, 2018.

[45] P. Willett, A. Zampetaki, K. Dudek et al., "Circulating micro-RNAs as novel biomarkers for platelet activation," Circulation Research, vol. 112, no. 4, pp. 595–600, 2013.

[46] M. Weber, M. B. Baker, R. S. Patel, A. A. Quyyumi, G. Bao, and C. D. Searles, "MicroRNA expression profile in CAD patients and the impact of ACEI/ARB," Cardiology Research and Practice, vol. 2011, Article ID 532915, 5 pages, 2011.

[47] T. Melak and H. W. Baynes, "Circulating microRNAs as possible biomarkers for coronary artery disease: a narrative review," EJHCC, vol. 30, no. 2, pp. 179–194, 2019.

[48] Z. Lai, P. Lin, X. Weng et al., "MicroRNA-574-5p promotes cell growth of vascular smooth muscle cells in the progression of coronary artery disease," Biomedicine & Pharmacotherapy, vol. 97, pp. 162–167, 2018.

[49] P. Howlett, J. K. Cleal, H. Wu et al., "MicroRNA 8059 as a marker for the presence and extent of coronary artery calcification," Open Heart, vol. 5, no. 1, article e000678, 2018.

[50] C. Schulte, S. Molz, S. Appelbaum et al., "miRNA-197 and miRNA-223 predict cardiovascular death in a cohort of patients with symptomatic coronary artery disease," PloS One, vol. 10, no. 12, article e0145930, 2016.

[51] T. Soeki, K. Yamaguchi, T. Niki et al., "Plasma microRNA-100 is associated with coronary plaque vulnerability," Circulation Journal, vol. 79, no. 2, pp. 413–418, 2015.

[52] X.-L. Ma, X. Yang, and R. Fan, "Screening of miRNA target genes in coronary artery disease by variational Bayesian Gaussian mixture model," Experimental and Therapeutic Medicine, vol. 17, no. 3, pp. 2129–2136, 2019.

[53] Y. Zhao and D. Srivastava, "A developmental view of microRNA function," Trends in Biochemical Sciences, vol. 32, no. 4, pp. 189–197, 2007.

[54] S. Anand, B. K. Majeti, L. M. Acevedo et al., "MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis," Nature Medicine, vol. 16, no. 8, pp. 909–914, 2010.

[55] Y. Suárez, C. Wang, T. D. Manes, and J. S. Pober, "Cutting edge TNF-induced microRNAs regulate TNF-induced expression of E-selectin and intercellular adhesion molecule-1 on human endothelial cells: feedback control of inflammation," Journal of Immunology, vol. 184, no. 1, pp. 21–25, 2010.

[56] P. Dentelli, A. Rosso, F. Orso, C. Olgası, D. Taverna, and M. F. Brizzi, "microRNA-222 controls neovascularization by regulating signal transducer and activator of transcription 5A expression," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 8, pp. 1562–1568, 2010.

[57] A. W. Ashton and J. A. Ware, "Thrombomodulin A2 receptor signaling inhibits vascular endothelial growth factor–induced endothelial cell differentiation and migration," Circulation Research, vol. 95, no. 4, pp. 372–379, 2004.

[58] J. E. Fish, M. M. Santoro, S. U. Morton et al., "miR-126 regulates angiogenic signaling and vascular integrity," Developmental Cell, vol. 15, no. 2, pp. 272–284, 2008.
chondrosarcoma cells,” Clinical Orthopaedics and Related Research, vol. 473, no. 3, pp. 907–913, 2015.

[71] F.-P. Shi, X.-H. Wang, H.-X. Zhang et al., “MiR-103 regulates the angiogenesis of ischemic stroke rats by targeting vascular endothelial growth factor (VEGF),” Iranian Journal of Basic Medical Sciences, vol. 21, no. 3, pp. 318–324, 2018.

[72] E. Fabbri, G. Montagner, N. Bianchi et al., “MicroRNA miR-93-5p regulates expression of IL-8 and VEGF in neuroblastoma SK-N-AS cells,” Oncology Reports, vol. 35, no. 5, pp. 2866–2872, 2016.

[73] E. Lutgens and M. J. Daemen, “Transforming growth factor-β: a local or systemic mediator of plaque stability?,” Circulation Research, vol. 89, no. 10, pp. 853–855, 2001.

[74] A. A. Ghazy, E. M. Osman, E. A. Rashwan, A. H. Gaballah, H. Mostafa, and S. Tawfik, “Relation between microRNA-21, transforming growth factor β and response to treatment among chronic hepatitis C patients,” Journal of Medical Virolgy, vol. 91, no. 12, pp. 2166–2173, 2019.

[75] G. De Santis, M. Ferracini, A. Biondani et al., “Altered miRNA expression in T regulatory cells in course of multiple sclerosis,” Journal of Neuroimmunology, vol. 226, no. 1-2, pp. 165–171, 2010.

[76] T. Thum, “MicroRNA therapeutics in cardiovascular medicine,” EMBO Molecular Medicine, vol. 4, no. 1, pp. 3–14, 2012.

[77] B. N. Davis, A. C. Hilyard, G. Lagna, and A. Hata, “SMAD proteins control DROSHA-mediated microRNA maturation,” Nature, vol. 454, no. 7200, pp. 56–61, 2008.

[78] C.-C. Tsai, S.-B. Wu, H.-C. Kau, and Y.-H. Wei, “Essential role of connective tissue growth factor (CTGF) in transforming growth factor-β1 (TGF-β1)-induced myofibroblast transdifferentiation from Graves’ orbital fibroblasts,” Scientific Reports, vol. 8, no. 1, p. 7276, 2018.

[79] B. T. Yu, N. Yu, Y. Wang et al., “Role of miR-133a in regulating TGF-β signaling pathway in myocardial fibrosis after acute myocardial infarction in rats,” European Review for Medical and Pharmaceutical Sciences, vol. 23, no. 19, pp. 8588–8597, 2019.

[80] B. A. Haider, A. S. Baras, M. N. McCall, J. A. Hertel, T. C. Cornish, and M. K. Halushka, “A critical evaluation of microRNA biomarkers in non-neoplastic disease,” PLoS One, vol. 9, no. 2, article e89565, 2014.

[81] A. Zernecke, K. Bidzhekov, H. Noels et al., “Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection,” Science Signaling, vol. 2, no. 100, article ra81, 2009.

[82] Y. Takahashi, M. Satoh, Y. Minami, T. Tabuchi, T. Itoh, and M. Nakamura, “Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels,” Clinical Science (London, England : 1979), vol. 119, no. 9, pp. 395–405, 2010.

[83] M. Molteni, S. Gemma, and C. Rossetti, “The role of toll-like receptor 4 in infectious and noninfectious inflammation,” Mediators of Inflammation, vol. 2016, Article ID 6978936, 9 pages, 2016.

[84] Y. Wang, X. Wang, Z. Li et al., “Two single nucleotide polymorphisms (rs2431697 and rs2910164) of miR-146a are associated with risk of coronary artery disease,” International Journal of Environmental Research and Public Health, vol. 14, no. 5, p. 514, 2017.

[85] N. Gao and L. Dong, “MicroRNA-146 regulates the inflammatory cytokines expression in vascular endothelial cells during sepsis,” Die Pharmazie, vol. 72, no. 11, pp. 700–704, 2017.

[86] D. Yang, X. Gao, L. Liu, Y. Chen, and W. Li, “MicroRNA-155 modulates the expression of pro-inflammatory cytokines in natural killer cells of rats exposed to chronic mild stress by regulation of ERK1/2 signaling pathway,” International Journal of Clinical and Experimental Pathology, vol. 9, pp. 1022–1029, 2016.

[87] X. Yang, J. Zhang, and Y. Ding, “Association of microRNA-155, interleukin 17A, and proteinuria in preeclampsia,” Medicine (Baltimore), vol. 96, no. 18, article e6509, 2017.

[88] Y. Gao and Z. Yu, “MicroRNA-16 inhibits interleukin-13-induced inflammatory cytokine secretion and mucus production in nasal epithelial cells by suppressing the 1xβ kinase β/nuclear factor-κB pathway,” Molecular Medicine Reports, vol. 18, no. 4, pp. 4042–4050, 2018.

[89] H. Y. Lee, H. Y. Lee, J. Y. Choi et al., “Inhibition of MicroRNA-21 by an antagonim ameliorates allergic inflammation in a mouse model of asthma,” Experimental Lung Research, vol. 43, no. 3, pp. 109–119, 2017.

[90] V. van der Heide, P. Mohnle, J. Rink, J. Briel, and S. Kreth, “Down-regulation of MicroRNA-31 in CD4+ T cells contributes to immunosuppression in human sepsis by promoting TH2 skewing,” Anesthesiology, vol. 124, no. 4, pp. 908–922, 2016.

[91] W. Sang, Y. Wang, C. Zhang et al., “MiR-150 impairs inflammatory cytokine production by targeting ARRB-2 after blocking CD28/B7 costimulatory pathway,” Immunology Letters, vol. 172, pp. 1–10, 2016.

[92] Y. Ando, G.-X. Yang, T. P. Kenny et al., “Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF-β receptor type II mouse,” Journal of Autoimmunity, vol. 41, pp. 111–119, 2013.

[93] H. Fayyad-Kazan, E. Hamade, R. Rouas et al., “Downregulation of microRNA-24 and -181 parallels the upregulation of IFN-γ secreted by activated human CD4 lymphocytes,” Human Immunology, vol. 75, no. 7, pp. 677–685, 2014.

[94] K. M. Smith, M. Guerra-de-Arellano, S. Costinean et al., “miR-29ab1 deficiency identifies a negative feedback loop controlling Th1 bias that is dysregulated in multiple sclerosis,” Journal of Immunology, vol. 189, no. 4, pp. 1567–1576, 2012.

[95] Y. Wu, J. Heinrichs, D. Bastian et al., “MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice,” Blood, vol. 126, no. 11, pp. 1314–1323, 2015.

[96] F. Chu, Y. Hu, Y. Zhou et al., “MicroRNA-126 deficiency enhanced the activation and function of CD4(+) T cells by elevating IRS-1 pathway,” Clinical and Experimental Immunology, vol. 191, no. 2, pp. 166–179, 2018.

[97] V. Ballesta, M. Zeni, K. K. Pedersen et al., “MicroRNA-210, microRNA-331, and microRNA-7 are differentially regulated in treated HIV-1-infected individuals and are associated with markers of systemic inflammation,” J Aids 2012, vol. 75, no. 7, pp. 685–691, 2012.

[98] F. Jansen, X. Yang, K. Baumann et al., “Endothelial microparticles reduce ICAM-1 expression in a microRNA-222-
dependent mechanism,” *Journal of Cellular and Molecular Medicine*, vol. 19, no. 9, pp. 2202–2214, 2015.

[99] T. Kasama, K. Ohtsuka, M. Sato, R. Takahashi, K. Wakabayashi, and K. Kobayashi, "Macrophage migration inhibitory factor: a multifunctional cytokine in rheumatic diseases,” *Arthritis*, vol. 2010, Article ID 106202, 10 pages, 2010.

[100] E. Bandres, N. Bitarte, F. Arias et al., "microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells,” *Clinical Cancer Research*, vol. 15, no. 7, pp. 2281–2290, 2009.

[101] S. Grundmann, F. P. Hans, S. Kinniry et al., "MicroRNA-100 regulates neovascularization by suppression of mammalian target of rapamycin in endothelial and vascular smooth muscle cells,” *Circulation*, vol. 123, no. 9, pp. 999–1009, 2011.

[102] S. S. S. Saravi, M. Ghazi-Khansari, S. E. Mehr, M. Nobakht, S. E. Mousavi, and A. R. Dehpour, "Contribution of mammalian target of rapamycin in the pathophysiology of cirrhotic cardiomyopathy,” *World Journal of Gastroenterology*, vol. 22, no. 19, pp. 4685–4694, 2016.

[103] J. Fan, X. Kou, Y. Yang, and N. Chen, "MicroRNA-regulated proinflammatory cytokines in sarcopenia,” *Mediators of Inflammation*, vol. 2016, Article ID 1438686, 9 pages, 2016.